Bechtold-Peters, Karoline, Niu, Sue, Schweizer, Daniel, Buecheler, Jakob, Brouillard, Christian, Callaway, Allen, Desai, Priyanka, Duggan, Naomi, Feng, Yiqing, Ihle, Nathan, Jacobson, Fred, Liu, Denfeng, Mayala, Padma, Morgan, Charles, Panek, Mark, Ruggiero, Andrea, Wright, Mark, Vriezen, Nienke and Wang, Xiangyang (2023) CMC Regulatory Considerations for Antibody-Drug Conjugates. Journal of pharmaceutical sciences. ISSN 1520-6017

Abstract

Antibody-drug conjugates unite the specificity and long circulation time of an antibody with the toxicity of a chemical cytostatic or otherwise active drug using appropriate chemical linkers to reduce systemic toxicity and increase therapeutic index. This combination of a large biological molecule and a small molecule creates an increase in complexity. Multiple production processes are required to produce the native antibody, the drug and the linker, followed by conjugation of afore mentioned entities to form the final antibody-drug conjugate. The connected processes further increase the number of points of control, resulting in necessity of additional specifications and intensified analytical characterization. By combining scientific understanding of the production processes with risk-based approaches, quality can be demonstrated at those points where control is required and redundant comparability studies, specifications or product characterization are avoided. Over the product development lifecycle, this will allow process qualification to focus on those areas critical to quality and prevent redundant studies. The structure of the module 3 common technical document for an ADC needs to reflect each of the production processes and the combined overall approach to quality. Historically, regulatory authorities have provided varied expectations on its structure. This paper provides an overview of essential information to be included and shows that multiple approaches work as long as adequate cross-referencing is included.

Item Type:	Article
Keywords:	Antibody-drug conjugates; drug-linker; payload; cytostatic; points of control
Date Deposited:	07 Oct 2023 00:45
Last Modified:	07 Oct 2023 00:45
URI:	https://oak.novartis.com/id/eprint/50195